| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure. In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent. Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval. Flavonoids are classified into seven structural classes: 1.flavanones -Nargenin, Naringin, Hesperetin, Isosakuranetin, Eriodictyol, Taxifolin 2.flavonols -Quercetin, Myrcetin, Fisetin, Rutin Morin, Kaempferol 3.chalcones -Butein, Xanthohumol, Isoliquintigenin, Cardamonin, Bavachalone, Xanthohumol, Phloretin 4.flavanols -Catechin, Gallocatechin, Epicatechin, Epigallocatechin-3-galate 5.anthocyanidins -Cyanidin 6.flavones -Chrysin, Apigenin, Luteolin, Vitexin, Orientin, Bacalein, Wogonin, Oroxylin A, Saponarin 7.isoflavonoids -Daidzein, Genistein, Glycitein Flavonoids — Cancer vs Normal Cell Pathway Map (Class-Level)
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Flavonoids — AD relevance: Flavonoid-rich diets and select supplements are studied for neuroprotection via antioxidant/anti-inflammatory effects, cerebrovascular support, and synaptic plasticity signaling. Effects are generally supportive and exposure/metabolite dependent. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Brain effects likely mediated by metabolites and chronic intake; large variability by subclass and microbiome. Clinical evidence status: Signals in small human trials (often with specific subclasses like cocoa flavanols/anthocyanins); AD disease-modification not established. Flavonoids — AD / Neurodegeneration Pathway Map (Class-Level)
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:227 Target#:143 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid